Frontiers in Psychiatry
July 19, 2021
Rita Kočárová, Jiřı́ Horáček, Robin Carhart‐Harris
95 citations
Psychedelic therapy may work across many psychiatric disorders by increasing neuronal and mental plasticity, which enhances the potential for change. Combined with psychotherapy, this plasticity can promote healthy adaptability and resilience, protecting long-term well-being. The authors propose that psychedelics' core action is transdiagnostic, offering prophylactic benefits beyond current treatments. They link candidate neurological and psychological markers to a predictive processing model, suggesting broad public health impact.
Central European journal of public health
September 1, 2022
Pavla Chomynová, Rita Kočárová, Filip Kňažek et al.
2 citations
About 5-6% of Czech adults (350-430 thousand people) have ever used classical psychedelics such as LSD, psilocybin mushrooms, or ayahuasca, rising to 28-30% when cannabis is included (1.9-2.1 million users). Current (past-year) use of classical psychedelics is 0.7-1.9% (50-130 thousand people), and 9-11% (590-750 thousand users) when cannabis is included. Users of psychedelics are more often male, younger, and single. No significant socio-demographic differences appear between users of classical psychedelics and recreational cannabis users, but both groups differ from non-users and users of other illicit drugs.
June 16, 2025
Rita Kočárová, Luisa Procházková, Michaela Plevková
Psychedelics can significantly enhance creativity, with a study revealing that 75% of participants reported increased artistic inspiration after using substances like psilocybin. In a sample of 100 individuals, those who engaged in creative tasks post-psychedelic use scored 30% higher on measures of originality compared to a control group. This intersection of psychology and art suggests that psychedelics may unlock new levels of creative potential, providing insights into the cognitive processes that drive artistic expression and innovation.